Tag Archives: biotechnology news

Ignorance is Bliss – for Teva

Posted on August 4, 2014 by Warren Woessner

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading →

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment

FDA Accepts First Biosimilar Application for Review

Posted on July 28, 2014 by Warren Woessner

In an important step forward for the introduction of “generic biological,” the FDA announced that it has accepted Sandoz’s application to market a generic version of Amgen’s Neupogen®, which stimulates white blood cell production. As you may recall, about two years … Continue reading →

Posted in FDA | Tagged , , , , , , , , , , , , | Leave a comment

PTO s. 101 Forum – Thumbs Down on Practitioners

Posted on May 12, 2014 by Warren Woessner

The USPTO held a four hour public forum on the new, disruptive s. 101 examination guidelines on Friday afternoon. The forum featured ten speakers from the patent bar, including Hans Sauer of BIO, Leslie Fishcher from Novartis, Barbara Fiacco (for … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 3 Comments

Isolated DNA and the “Hand of Man”

Posted on April 28, 2014 by Warren Woessner

Editors Notes: Apart from a fine survey of the case law on patent-eligibility of not-so natural products, Paul Cole suggests that, in view of the incomplete and/or indirect description of the BRACA sequences that Myriad claimed, there may well be … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment